Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax | Synapse
April 1, 2024Open Access
Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Key Points
Key points are not available for this paper at this time.
Abstract
Supplemental Figure 1: Overall survival and event-free survival in HMA-naïve patients by response.